Disclosures for "Early-life social determinants of SCA6 age at onset, severity, and progression")
-
Tiffany Chen has nothing to disclose.
-
Ms. Casey has nothing to disclose.
-
Dr. Lin has a non-compensated relationship as a Secretary with Broadway for Ataxia Foundation (a 501 (c) (3) non-profit organization) that is relevant to AAN interests or activities.
-
An immediate family member of Dr. Boyle has stock in Ionis Pharmaceuticals. The institution of Dr. Boyle has received research support from Bristol Myers Squibb.
-
Dr. Schmahmann has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medavante. Dr. Schmahmann has stock in Cadent. The institution of Dr. Schmahmann has received research support from National Ataxia Foundation. The institution of Dr. Schmahmann has received research support from Biohaven. Dr. Schmahmann has received intellectual property interests from a discovery or technology relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care.
-
Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has received stock or an ownership interest from biohaven pharmaceuticals.
-
Dr. Kuo has nothing to disclose.
-
Dr. Gomez has nothing to disclose.